<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02271581</url>
  </required_header>
  <id_info>
    <org_study_id>INSYNC</org_study_id>
    <nct_id>NCT02271581</nct_id>
  </id_info>
  <brief_title>Effect of Symptom Management on Inflammation and Survival in Metastatic Lung Cancer</brief_title>
  <official_title>INSYNC: Leo Jenkins Cancer Center (LJCC) - Symptom Management Service (SMS) Protocol -Phase II Trial Regarding The Effect Of Comprehensive Symptom Management On Inflammation And Survival In Metastatic Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Leo W. Jenkins Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Leo W. Jenkins Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      There is a growing body of evidence that implicates inflammation as a mechanism of disease&#xD;
      progression and reduced survival in patients with advanced cancer. Elevated c-reactive&#xD;
      protein levels have been shown to be associated with reduced performance status, specific&#xD;
      cancer related symptoms and reduced overall survival. C-reactive protein levels are a&#xD;
      surrogate for IL-6 expression. IL-6 is part of an inflammatory signature predicting cancer&#xD;
      recurrence. VeriStrat® is a multivariate test which measures protein expression related to a&#xD;
      host/tumor interaction mediated by inflammation. The investigators hope to examine the&#xD;
      relationship between quality of life outcomes per FACT-L survey and correlate them with&#xD;
      changes in c-reactive protein levels and the VeriStrat® status. The hypothesis of this study&#xD;
      is that the remarkable survival benefit in the Temel study is mediated by reduced&#xD;
      inflammation with improvement of symptom control.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2014</start_date>
  <completion_date type="Actual">April 19, 2019</completion_date>
  <primary_completion_date type="Actual">April 19, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Patients will be followed for 5 years after enrolling last patient</time_frame>
    <description>Overall survival from diagnosis until death from any cause</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients who convert from c-reactive protein 'high' (&gt; 10 mg/L) to 'low' (&lt;10 mg/L)</measure>
    <time_frame>10 months</time_frame>
    <description>Baseline versus 4 months&#xD;
Baseline versus 10 months&#xD;
4 months versus 10 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life (QOL) indicators per FACT-L score and the following at baseline, 4 months and 10 months groups</measure>
    <time_frame>10 months</time_frame>
    <description>VeriStrat &quot;Good&quot; and CRP &quot;low&quot; (&lt;10 mg/L)&#xD;
VeriStrat &quot;Good&quot; and CRP &quot;high&quot; (&gt;10 mg/L)&#xD;
VeriStrat &quot;Poor&quot; and CRP &quot;low&quot; (&lt;10 mg/L)&#xD;
VeriStrat &quot;Poor&quot; and CRP &quot;high&quot; (&gt;10 mg/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in VeriStrat status</measure>
    <time_frame>10 months</time_frame>
    <description>Percentage of patients who convert from &quot;poor&quot; to &quot;good&quot;</description>
  </secondary_outcome>
  <enrollment type="Actual">38</enrollment>
  <condition>Lung Neoplasms</condition>
  <condition>Carcinoma, Non-Small-Cell Lung</condition>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Retain serum samples draw at baseline, 4 months, 10 months for storage and analysis by&#xD;
      Biodesix Laboratories.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients diagnosed with metastatic (stage IV) non-small cell lung cancer&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Confirmed diagnosis of stage IV non-small cell lung cancer&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2&#xD;
&#xD;
          -  Able to read and respond to questions in English&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Small Cell Lung Cancer&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Geoffrey Stroud, PharmD, BCOP, CPP</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brody School of Medicine at ECU</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Leo Jenkins Cancer Center</name>
      <address>
        <city>Greenville</city>
        <state>North Carolina</state>
        <zip>27834</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>July 30, 2014</study_first_submitted>
  <study_first_submitted_qc>October 20, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 22, 2014</study_first_posted>
  <last_update_submitted>November 3, 2020</last_update_submitted>
  <last_update_submitted_qc>November 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

